Login / Signup

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.

Nicola J CurtinYvette DrewSweta Sharma-Saha
Published in: Nature reviews. Clinical oncology (2020)
Keyphrases
  • dna damage
  • dna repair
  • stem cells
  • oxidative stress
  • mesenchymal stem cells
  • breast cancer risk
  • bone marrow
  • cell therapy